Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Regulatory Reform Council to Monitor Progress on Proposed Pricing Overhaul of Innovative Drugs
September 17, 2014
- MHLW Orders Revision of Package Insert for Lyrica
September 17, 2014
- PMDA Issues Alert on Administration of ARBs and ACE Inhibitors in Pregnant Women
September 12, 2014
- US FDA Approves Obesity Treatment Contrave; Takeda Has Marketing Rights
September 12, 2014
- EAD Director to Visit 5 Public Hospital Groups to Encourage Quick Settlement of Price Negotiations
September 12, 2014
- Chuikyo at Odds over Disclosure of Cost-Effectiveness Case Study Data to Companies
September 11, 2014
- Chuikyo’s Drug Pricing Panel to Continue Discussions on Penalties and Actions against Novartis
September 11, 2014
- Drug Costs Made Up 21.9% of Japan Healthcare Spending in FY2011: MHLW
September 11, 2014
- MLHW to Issue Development Request for Vaccines that Require Fewer Doses
September 11, 2014
- New Minister Eager to Keep 30% Deduction Cap for R&D Tax Credit System
September 10, 2014
- Jichi Medical University President Seen as Prime Candidate for Japan NIH Head
September 10, 2014
- Takeda Chairman Removed from Competitiveness Panel
September 9, 2014
- Editor’s Pick: Five Healthcare News Headlines for August 25 – September 5
September 8, 2014
- Two Female Lawmakers Named New Senior Vice Health Ministers
September 8, 2014
- PAFSC’s Second Committee Backs Approval of Nobelpharma’s Anticancer Drug, MSD’s Hepatitis C Treatment
September 8, 2014
- PAFSC’s First Committee Supports Approval of Lixiana’s Additional Indications
September 5, 2014
- New Health Minister Plays it Safe, Promises to Follow Cabinet Decision on NHI Price Revision Frequency
September 5, 2014
- Industry on Alert as Reformist Shiozaki Tapped as New Health Minister
September 4, 2014
- PFSB Issues Notification on Submission of Package Inserts Under New Act
September 4, 2014
- LDP’s Niwa Says Treatment of Post-HPV Vaccine Adverse Reactions Top Priority
September 3, 2014
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…